Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 15.56 -4.13% -0.67
CYCN closed down 4.13 percent on Thursday, April 18, 2019, on 41 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical CYCN trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Hot IPO Pullback Bullish Swing Setup -4.13%
Inside Day Range Contraction -4.13%
Down 3 Days in a Row Weakness -4.13%
Hot IPO Pullback Bullish Swing Setup -8.52%
Shooting Star Candlestick Bearish -14.93%
New 52 Week Closing High Bullish -15.71%
Up 3 Days in a Row Strength -15.71%

Older signals for CYCN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Medicine Biopharmaceutical Medical Specialties Diseases Organ Systems Heart Failure Kidney Diseases Diabetic Nephropathy Cardiomyopathy Sickle Cell Disease
Is CYCN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.0
52 Week Low 13.9
Average Volume 335,582
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 17.203
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line -0.1864
MACD Signal Line -0.049
MACD Histogram -0.1374
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.53
Resistance 3 (R3) 18.68 17.83 18.04
Resistance 2 (R2) 17.83 17.08 17.76 17.87
Resistance 1 (R1) 16.70 16.61 16.28 16.55 17.70
Pivot Point 15.85 15.85 15.64 15.78 15.85
Support 1 (S1) 14.72 15.10 14.30 14.57 13.42
Support 2 (S2) 13.87 14.63 13.80 13.25
Support 3 (S3) 12.74 13.87 13.09
Support 4 (S4) 12.59